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JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in
transduction of extracellular signals from cytokines and growth factors involved in hematopoiesis, immune
regulation, fertility, lactation, growth and embryogenesis. JAK family contains four cytoplasmic tyrosine kinases,
JAK1-3 and Tyk2. Seven STAT proteins have been identified in human cells, STAT1-6, including STAT5a and STAT5b.
Negative regulators of JAK–STAT pathways include tyrosine phosphatases (SHP1 and 2, CD45), protein inhibitors of
activated STATs (PIAS), suppressors of cytokine signaling (SOCS) proteins, and cytokine-inducible SH2-containing
protein (CIS). Dysregulation of JAK-STAT pathway have been found to be key events in a variety of hematological
malignancies. JAK inhibitors are among the first successful agents reaching clinical application. Ruxolitinib (Jakafi), a
non-selective inhibitor of JAK1 & 2, has been approved by FDA for patients with intermediate to high risk primary
or secondary myelofibrosis. This review will also summarize early data on selective JAK inhibitors, including
SAR302503 (TG101348), lestaurtinib (CEP701), CYT387, SB1518 (pacritinib), LY2784544, XL019, BMS-911543, NS-018,
and AZD1480.Introduction
JAK-STAT (Janus associated kinase-signal transducer
and activator of transcription) pathway is one of the cri-
tical intracellular signaling cascades in transduction of
extracellular signals to the nucleus to control gene expres-
sion. A variety of cytokines and growth factors complete
their physiological tasks through JAK-STAT pathway, in-
cluding hematopoiesis, immune-regulation, fertility, lacta-
tion, growth and embryogenesis [1-6].
JAK family contains four cytoplasmic tyrosine kinases,
JAK1-3 and Tyk2 [7]. These kinases bind to the juxta-
membrane region of cytokine receptors [8]. Each molecule
contains seven JAK homology domains (JH1-7). The car-
boxyl JH1 domain contains the catalytic activity, whereas
N-terminal JH7 domain is responsible for receptor bind-
ing. JH2 domain has significant homology to JH1 but lacks
enzymatic activity and therefore is a pseudo-kinase do-
main. Binding of a ligand to its receptor results in recep-
tor dimerization, leading to activation of the JAK kinase* Correspondence: DELONG_LIU@NYMC.EDU
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reproduction in any medium, provided the oractivity. Subsequently activated JAKs phosphorylate cy-
toplasmic domain of the receptor [9]. Activated JAK-
cytokine receptor complex recruits and phosphorylates
specific cytoplasmic transcription factors called STAT
proteins [10]. Seven STAT proteins have been identified
in human cells, STAT1-6, including STAT5a and STAT5b
[7]. Phosphorylation of specific STAT proteins results in
their dimerization and subsequent translocation into the
nucleus to interact with various regulatory elements for
gene expression (Figure 1) [11,12].Regulation of JAK-STAT pathway
Three major mechanisms have been implicated to ne-
gatively regulate the JAK-STAT pathway [11]. Figure 1
depicts the positive and negative regulation of the JAK-
STAT pathway.Tyrosine phosphatases
Src homology-2 (SH2) containing tyrosine phosphatase
and CD45 tyrosine phosphatase play a major role in modu-
lating JAK-STAT pathway. SH2 containing tyrosine phos-
phatases include SHP1 and SHP2 (shatterproof 1 & 2).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Signaling cascade of JAK-STAT pathway. Binding of the ligand to cytokine receptor induces receptor dimerization and activation of
receptor associated JAK kinase, which in turn phosphorylates STAT proteins. After forming a homodimer, STAT proteins translocate to the nucleus
to control gene expression. Negative regulation of the JAK-STAT pathway is provided by phospho-tyrosine phosphatases (PTP), member for SOCS
family proteins and PIAS proteins (shown in red).
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tyrosine residues present on activated receptors, JAKs or
STAT proteins, leading to dephosphorylation of the sub-
strates. SHP1 is mainly expressed in hematopoietic cells,
epithelial and smooth muscle cells whereas SHP2 is ubi-
quitous. The expression of SHP1 gene was found to be
silenced by promoter hypermethylation in various hemato-
logical malignancies [10]. CD45 transmembrane tyrosine
phosphatase is the second type of tyrosine phosphatase
that negatively regulates JAK-STAT pathway. CD45, the
leukocyte common antigen, is expressed in hematopoietic
cells. It has two phosphatase domains in its intracellular
region, though only one is active. Mice deficient for CD45
show hyper-activation of JAK1 and JAK3 [10].
Protein inhibitors of activated STATs (PIAS)
PIAS family consists of PIAS1, PIAS3, PIASx and PIASy.
Biochemical assays have shown that PIAS3 and PIASx in-
teract with STAT3 and STAT4 respectively, while PIAS1
and PIASy with STAT1 [13,14]. PIAS1 and PIAS3 exert
negative regulation by blocking the DNA binding of
STAT1 and STAT3, respectively [15,16]. On the other
hand, PIASx and PIASy repress the transcriptional ac-
tivity of STAT1 and STAT4 by recruiting co-repressor
molecules such as histone deacetylases [17].
Suppressors of cytokine signaling (SOCS) proteins
The suppressor of cytokine signaling (SOCS) family is
composed of SOCS-1 to SOCS-7 and cytokine-inducibleSH2-containing protein (CIS). SOCS proteins are cyto-
kine-induced negative feedback-loop regulators of JAK-
STAT signaling. Each member protein in this family has
a central SH2 domain, variable amino-terminal domain
and a carboxy-terminal of 40 amino acids module known
as SOCS box. The central SH2 domain directs the target
binding of each CIS/SOCS protein [18]. Three mecha-
nisms have been proposed by which a SOCS protein
provides negative modulation. First, SOCS binds the phos-
pho-tyrosine residues on the receptors and physically
blocks the STATs from binding to its receptors. Second,
SOCS proteins can bind directly to its specific JAKs or to
the receptors and inhibit the corresponding JAK kinase
activity. Third, SOCS associate with the elongin BC com-
plex and cullin 2, accelerating the ubiquination of JAKs
and presumably the receptors [19].
Endosomal degradation of JAK/receptor complex through
receptor mediated endocytosis appears to be another me-
chanism involved in the regulation of the pathway. STAT5ß
dimerizes with the full-length, wild-type protein, STAT5α,
upon activation. This leads to negative regulation of the
JAK-STAT signaling cascade in addition to the major me-
chanisms described above [20].JAK-STAT pathway and hematological
malignancies
Dysregulation in JAK-STAT pathway have been described
in a variety of hematological malignancies, especially in
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tiation and progression of respective diseases.Myeloproliferative Neoplasms (MPN)
Ph negative MPNs
Short interfering RNA and JAK2 inhibitor (AG490) have
been used to study the activity of JAK2. JAK2 was shown
to be central to the erythropoietin-independent eryth-
roid proliferation in polycythemia vera (PV). A common
mutation (V617F) in the JH2 pseudo-kinase domain of
JAK2 was shown in 80% of the patients [21]. This results
in constitutive activation of STAT5 and a malignant
phenotype [22]. Other investigators confirmed the fact
and showed that 30-50% of patients with essential throm-
bocythemia (ET) and primary myelofibrosis (PMF) also
harbor the same mutation [23-25].
Allelic burden of JAK2V617F was found to play an im-
portant role in determining a distinct clinico-pathologic
phenotype from the same mutation [22,26]. It is sug-
gested by the fact that homozygous JAK2V617F mu-
tation is 30% in PV compared to 2-4% in ET [22,26].
Transgenic mouse models and clinical cases support
the gene-dosage model for MPN pathogenesis. It was
observed that high allele burden leads to PV pheno-
type, whereas reduction in allelic burden leads to ET
[22,27-29].
In patients with PV who are negative for JAK2V617F,
Scott et al., used a candidate gene approach to search
for alleles that can activate JAK signaling. Their work
demonstrated at least 8 distinct mutations involving resi-
dues 538 to 543 in exon 12 region of JAK2 [29].
Irrespective of JAK2V617F status, patients with PV
exhibits high STAT3 and 5 activities, patients with ET
have high STAT3 activity, whereas patients with PMF
showed low activities of both STAT3 and 5. It is evident
that preferential activation of JAK2–STAT5 or JAK2–
STAT3 signaling determines PV, ET and PMF pheno-
type. However patients with JAK2V617F-negative ET or
PMF may harbor mutations in other genes in JAK–
STAT pathway [30].Atypical MPNs
Rare JAK2 gene rearrangement can result in atypical
form of chronic myeloid leukemia (aCML). These gene
rearrangements include PCM1-JAK2, TEL-JAK2 and
BCR-JAK2 [31-33]. Rarely, JAK2V617F mutation can pre-
sent phenotypically as chronic myelomonocytic leuke-
mia /aCML.
PCM1-JAK2 gene rearrangement was discovered in
the translocation, t(8;9)(p22;p24). It is reported in few
cases with atypical CML, chronic eosinophilic leukemia,
AML (M2, M6), pre B-ALL and T-cell lymphoma.Lymphoma and lymphoid leukemia
T-cell lymphoma and leukemia
JAK1 gene plays a unique role in lymphohematopoiesis.
Flex et al., showed several acquired JAK1 missense
mutations in adult lymphoblastic leukemia, especially in
T-cell precursor type where it accounted for 18% of the
cases. It was associated with advanced age and poor
prognosis [34-36].
Translocation between short-arm of chromosome 9
(harboring JAK2 gene) and 12, t(9;12)(p24;p13) results
in the formation of a fusion protein, TEL-JAK2. This
results in constitutive JAK2 activation. It was found in a
case of childhood T-cell acute lymphoblastic leukemia
[37] and in a case with pre-B-cell ALL [33].
Adult T-cell Leukemia (HTLV-1 positive)
Human T-cell lymphotropic virus-1 encoded Tax protein
suppresses apoptosis through constitutive activation of
the NFκB pathway. This is sufficient for immortalization
of CD4+ lymphocytes. HTLV-1 infected T-cells over-ex-
press IL-2, IL-15 as well as IL-2 and IL-15 receptors by
Tax-induced NFκB activation. These in turn activate
JAK3-STAT5 pathway leading to lymphocyte prolifera-
tion and adult T-cell lymphoma /leukemia [38].
T-cell Large Granular Lymphocytic Leukemia, Anaplastic
Large cell Lymphoma, Angioimmunoblastic Lymphoma and
Sezary Syndrome
Dysregulation of STAT proteins also contributes to the
pathogenesis of various types of lymphoid malignancies.
Schade et al., reported increase activity of STAT3 in T-
cell large granular lymphocytic leukemia [39]. Constitu-
tive activation of STAT3 & 5 was also found to be an
important event in the pathogenesis of anaplastic large
cell lymphoma, T-cell angioimmunoblastic lymphoma
and Sezary syndrome [40,41].
B-Cell lymphoma and leukemia
Acute lymphoblastic leukemia
Kearney et al., performed sequencing of exon 14 of
JAK2 gene in patients with Down syndrome associated
ALL. An acquired somatic point mutation invovling resi-
due R683 was found in 28% of cases [42]. A different
mutation in JAK2 gene in a patient with Down syn-
drome associated precursor B-cell lymphoblastic
leukemia was reported by Malinge et al., This mutation
was in-frame deletion of five-amino acid residues from
position 682 to 686, named as IREED mutation, in the
pseudokinase domain of JAK2. This IREED mutant
remains constitutively active and induces cytokine in-
dependence in Ba/F3 cells [43].
Another JAK2 mutation involves fusion with SSBP2 in
t(5;9)(q14.1;p24.1) translocation. It was detected in a pa-
tient with pre B-cell ALL [44].
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Constitutive activation of STAT1 & 3 was noticed in
transformed B-cells in patients with chronic lymphocytic
leukemia (CLL). Activated STAT1 & 3 proteins in ma-
lignant B-cells were phosporylated at serine instead of
tyrosine residue. It remained uncertain whether activated
STAT involved directly in the pathophysiology of this
disease or represented a pure epi-phenomenon [45].
Primary mediastinal B-cell lymphoma
A bi-allelic mutation in SOCS-1 has been reported in
primary mediastinal B-cell lymphoma. This results in
delayed turnover of phosphorylated JAK2 and increased
activity of STAT5, which may explain the uncontrolled
growth of malignant cells [46].
Hodgkin lymphoma
Gene rearrangement by translocation involving JAK2,
t(4;9)(q21;p24), has been reported in 2 cases of classic
Hodgkin lymphoma by a group from Belgium [47]. This
gene re-arrangement creates a novel fusion product,
SEC31A-JAK2. This oncogenic SEC31A-JAK2 has consti-
tutively active tyrosine kinase activity. Mutations of SOCS-
1 have also been identified in Hodgkin lymphoma [48].
Myeloid leukemia
Acute myeloid leukemia
Increased activity of STAT3 has been reported in 20-50%
of AML patients while STAT5 and STAT1 activation
is uncommon [49,50]. The pathologic value of activated
STAT3 in AML is unclear. It was also found in acute pro-
myelocytic leukemia (APL). An interstitial deletion within
chromosome 17 has been described to result in STAT5b-
RARα fusion protein. This was implied to serve as a key
pathogenic event in a patient with APL [51]. Transfor-
mation from severe congenital neutropenia due to trun-
cated G-CSF receptor to AML also involves dysregulation
of STAT proteins. Truncated G-CSF receptor lacks a
crucial binding site for SOCS-3, thus relieving inhibition
of STAT5, but not of STAT3. This favors myeloid pro-
liferation over differentiation. These truncated receptors
are also resistant to down modulation through ubiqui-
nation [52].
Rare point mutations, one in JAK2 (T875N) and three
in JAK3 (A572V, V722I, P132T), have been described in
patients with acute megakaryocytic luekemia [52]. PCM1-
JAK2 gene rearrangement mentioned above was found in
M2 and M6 AML [36].
Myelodysplastic syndrome (MDS)
Perturbation in JAK-STAT pathway is rare in MDS. Only
4.2% patients with MDS were found to harbor JAK2V617F
mutation in a large screening series [53]. Of interest is a
disease entity called refractory anemia with ringedsideroblast associated with marked thrombocytosis
(RARS-t). These patients have features of both MDS and
MPN. It was recently shown that 6 out of 9 (67%) patients
with RARS-t have JAK2V617F mutation [54].
Multiple myeloma
Constitutive expression of STAT3 has been seen fre-
quently in patients with multiple myeloma and lymphoma
[55]. However, overexpression of anti-apoptotic proteins
of Bcl-2, Bcl-XL and Mcl-1 may not rely on STAT3 activa-
tion. The role of this pathway in pathogenesis of myeloma
remains to be determined [56].
Novel inhibitors of JAK-STAT pathway
The specific and profound involvement of JAK-STAT
pathway in various hematological malignancies, espe-
cially Bcr-Abl negative MPNs, makes them ideal targets
for pharmacological intervention [57]. Several strategies
have been proposed to inhibit or modulate this pathway
[58,59]. JAK inhibitors are among the first successful
agents reaching clinical application [60,61].
JAK inhibitors
There are at least 10 different JAK inhibitors undergoing
various phases of clinical trials (Table 1). Ruxolitinib
(Jakafi manufactured by Incyte, Inc) has been approved
by FDA for patients with intermediate- to high- risk pri-
mary or secondary myelofibrosis.
Ruxolitinib
Ruxolitinib (INCB018424) is a non-selective JAK1 &
2 inhibitor. Multiple phase I/II studies in various he-
matological malignancies are underway. Among these,
results are most mature for PMF and post –ET /PV
myelofibrosis.
Phase I/II studies
A total of 153 patients with myelofibrosis were recrui-
ted in a phase I/II study. Dose limiting toxicity was
thrombocytopenia with maximum tolerated dose of
25 mg twice daily. Effect on JAK2V617F allele burden
or bone marrow fibrosis was insignificant [62]. After a
longer follow up, it was described that abrupt discon-
tinuation can lead to serious adverse events like acute
relapse of constitutional symptoms, rapid and painful
enlargement of spleen and shock. By the time of last re-
port on the follow up of these patients 35% of patient
died and 10% transformed to leukemia [63,64].
Eghtedar et al., reported a phase I/II study of ruxoli-
tinib in patients with relapsed /refractory AML. This
study has shown 7% complete remission rate. It was no-
ticed that patients who achieved complete remission
were those with post-MPN AML [65].
Table 1 JAK inhibitors in clinical trials
Drugs JAK
Target
Non-JAK Target Trials: status Disease under study
(Ref)
INCB018424 (Ruxolitinib) JAK1 & 2 NR III: Reported PMF, Post ET/PV MF,
III: recruiting PV (intolerant or resistant to HU)
FDA Approved II: Recruiting PV, ET
[62-67] I/II: Recruiting AML/ALL (Relapse/Refractory)
II: Completed MM (Relapse/Refractory)
II: Recruiting DLBCL/T-Cell Lymphoma
II: Active Advanced Hem Malignancies
SAR302503 JAK2 FLT3 III: Recruiting PMF
(TG101348) RET II: Recruiting PV, ET
[70]
CEP-701 JAK2 FLT3 II: Completed ET, PV
(Lestaurtinib) JAK3 VEGFR2 II: Completed AML (FLT3)
[71,72] TRKA III: Recruiting ALL (children)
RET II: Recruiting PMF
CYT387 JAK1,2 PKD3, PRKD1, CDK2, ROCK2, JNK1 II: Recruiting PMF, Post PV/ET MF
[77,78] Tyk2
SB1518 JAK2 FLT3 II: Completed PMF
[83,84] II: Completed Adv Myeloid malignancies
II: Completed Adv Lymphoid malignancies
II: Recruiting MDS
LY2784544 JAK2V617F NA I/II: Recruiting PMF, ET, PV
[85]
XL019 JAK2 NA I: Terminated PMF
[86]
AZD1480 JAK1-3 FGFR1, FLT4, ARK5, ALK4, Aurora-A I/II: Active PMF, Post ET/PV MF
[91]
BMS-911543 JAK2 No information I/II: active PMF
[90]
NS018 JAK2 Src Kinases I/II: active PMF, Post ET/PV MF
[89]
Ref, references; NR, none reported; HU, hydroxyurea; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; MM, multiple Myeloma; DLBCL, diffuse large
B-cell lymphoma.
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Ruxolitinib has undergone 2 separate randomized con-
trolled trials, referred to as the COntrolled MyeloFibrosis
study with ORal JAK inhibitor Treatment (COMFORT) I
& II (Table 2) [66,67]. Patients were randomized between
ruxolitinib vs placebo (COMFORT I) or best available
therapy (COMFORT II). Patients with PMF or post –ET
/PV myelofibrosis must have high or intermediate inter-
national prognostic scores, palpable spleen ≥5 cm below
the left costal margin, and platelet count equal or greater
than 100 × 109 /L. Patients were recruited irrespective
of JAK2 gene mutation status. Differences in the designof these trials and major outcomes are summarized in
Table 2.
These trials support the palliative role of ruxolitinib
which significantly reduced spleen volume and consti-
tutional symptoms. The responses were not specific for
JAK2 mutation.
SAR302503 (TG101348)
SAR302503 is a selective JAK2 inhibitor with activity
on both wild type and mutant JAK2 [68,69]. Fifty nine
patients were enrolled in a multi-center phase I/II trial
with high-or- intermediate-risk primary or post-PV/ET
Table 2 COMFORT-I & II trials on ruxolitinib
Methodology COMFORT-I COMFORT-II
Design 1:1 randomization, vs. placebo 2:1 randomization, vs. best available therapy
Number of patients 155 (ruxolitib) vs. 154 (placebo) 146 (ruxolitinib) vs. 73 (BAT)
Dose of ruxolitinib 15-20 mg twice daily based on platelet count 15-20 mg twice daily based on platelet count
Primary end point reduction in spleen size > 35% at 24 week reduction of spleen size > 35% at 48 week
Results
35% reduction in spleen size 42% vs. 0.7% at 24 week 28% vs. 0% at 48 week
Duration of spleen response * 67% patient maintained the spleen response for 48 weeks 80% maintained the response at 12 month follow up
Major Adverse events: Anemia (45%), Thrombocytopenia (13%), headache, pyrexia Anemia, Diarrhea, Arthralgia, fatigue, abdominal pain
Discontinuation Rate 11% vs. 10.6% 8% vs. 5%
BAT, best available therapy; * , secondary end-points ; QOL, quality of life ; ns, non significant.
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ter than 50 x 109 /L were eligible. Reversible increase in
serum amylase was the dose limiting toxicity. Serious
adverse events included mainly myelosuppression and
gastrointestinal toxicity. A spleen response of 47% was
seen after one year of treatment. JAK2V617F allele burden
was significantly decreased at 6 months in mutation-
positive patients (n = 51; P = .04). The response was
higher in patients with allele burden greater than 20%
(n = 23; P < .01) [70]. A multinational, randomized, pla-
cebo controlled phase III trial has been launched recently
for patients with high risk myelofibrosis.Lestaurtinib (CEP701)
Lestaurtinib is an orally available indolocarbazole deriva-
tive. It was originally identified as an inhibitor of the
neurotropin receptor TrkA. It was found to also inhibit
FLT3, JAK2 and JAK3. Due to its strong activity against
FLT3, it is under investigation in patients with acute
leukemia. A phase I/II study of lestaurtinib was done
in 22 patients with JAK2-mutated myelofibrosis. The
patients received 80 mg twice-daily. The response rate
was 27%. The median duration of response was mo-
re than 14 months. However, bone marrow fibrosis
or JAK2V617F allele burden was not significantly al-
tered [71].
In another phase 2 study, lestaurtinib was given to 39
high-risk patients with JAK2V617F-positive PV (n=27)
or ET (n=12). After 18 weeks of treatment, a significant
decrease in spleen size was reported in 83% of the
patients. Six patient developed thrombosis. The increase
in the thrombotic events remains a concern for this
agent [72].CYT387
CYT387 is an ATP-competitive small molecule JAK1/
JAK2 inhibitor [73-76]. It has an IC50 of 11 and 18 nM
for JAK1 and JAK2, respectively. Unlike lestaurtinib,CYT387 has significantly less activity against other ki-
nases, including JAK3 (IC50=0.16 μM).
One hundred sixty three patients with high- or in-
termediate- risk myelofibrosis were enrolled in a phase
I/II trial of CYT387. The median duration of treatment
was 6.6 months. Dose limiting toxicities included hyper-
lipasemia and headaches. Maximum tolerated dose was
300 mg/day. The response rates for reduction of spleen
size, anemia, and constitutional symptom were 45%,
50%, and more than 50%, respectively. It is interesting to
note that responses were also seen in patients who had
previously failed ruxolitinib or SAR302503. Surprisingly,
58% of transfusion-dependent patients became transfusion-
independent. Transient light headedness and hypotension
were the common adverse events. Treatment-related severe
anemia was infrequent (< 1%). This property separates it
from ruxolitinib and SAR302503 [77,78].SB1518 (pacritinib)
Pacritinib is another orally bioavailable ATP-competi-
tive small molecule inhibitor of JAK2 and the mutant
JAK2V617F [79-82]. It inhibitis JAK-STAT signaling
pathway through caspase-dependent apoptosis. In a
phase I/II trial, 34 patients with primary or post PV/ET
myelofibrosis were enrolled. The median time on study
was 8.2 months. Patients with low blood counts were
not excluded. Most common adverse events were diar-
rhea, nausea and vomiting. The primary end point was
spleen response, which was 32%. The median duration
of spleen response has not been reached at the recent
update [83].
In another phase I trial, 30 patients with relapsed/
refractory lymphoma were enrolled. The dose was es-
calated from 200–600 mg/day. Severe adverse events in-
cluded cytopenia, internal hemorrhage, various infections
and abdominal distention. No patient achieved complete
remission. Three patients had partial remission and 13
patients had stable disease [84]. Phase II trial is ongoing.
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LY2784544 is a selective mutant JAK2 kinase inhibitor
with an IC50 of 68 nM. This molecule selectively inhib-
ited the JAK2 V617F-STAT5 signaling at a concentration
that was 41-fold lower than that needed for the wild type
(WT) JAK2 signaling (IC50 = 55 nM for V617F vs. 2260
nM for WT ) [60]. A phase I/II trial recruited 19 pa-
tients with Ph negative MPN. Maximum tolerated dose
was 120 mg/day. Spleen response was 22% for patients
with MF. JAK2V617F allele burden was not significantly
decreased. Main adverse events included diarrhea, nau-
sea, anemia and electrolyte imbalance [85].
XL019
XL019 represents another oral selective JAK2 inhibitor
(IC50= 2nM for JAK2, 130 nM for JAK1, 250 nM for
JAK3, 340 nM for TYK2) [86,87]. A phase I study
recruited 21 patients with myelofibrosis. 16 patients had
JAK2V617F, one had MPL W515F. Dose ranged from 25
to 300 mg. Surprisingly, there was no hematological ad-
verse events. Improvement in clinical outcome observed
in all patients with JAK2V617F or MPL activating muta-
tions [86]. Despite these results, further development of
clinical trials using XL019 was aborted out of the con-
cerns for neurologic toxicities [88].
NS-018, BMS-911543 and AZD1480
These JAK inhibitors are also selective JAK inhibitors at
very early stage of drug development [48,89-91]. NS-018
was shown to be highly selective against JAK2 with IC50
<1 nM [89]. It had 30–50 fold greater selectivity for
JAK2 over other JAK-family kinases, such as JAK1, JAK3
and Tyk2. BMS-911543 is a functionally selective JAK2
inhibitor [90]. AZD1480 has been shown both in vitro
and in vivo to inhibit the growth of multiple malignan-
cies by inhibiting phosphorylation of JAK2, STAT3 and
MAPK signaling proteins [91-99]. Clinical investigations
on these agents are underway.
Conclusion and future directions
Currently the benefits of therapy with JAK inhibitors in
MPNs are palliative in nature. This is suggested by in-
ability of ruxolitinib to influence the natural history of
the diseases and by the fact that the responses are unre-
lated to JAK mutation status. JAK2V617F mutation may
be a key event but not necessarily a primary factor driv-
ing the tumorigenesis of MPNs. Other molecular events
may precede the acquisition of JAK2V617F mutation in
these disorders. Novel selective JAK2 inhibitors are the
active focus for further clinical investigations [60,61,88].
In addition to JAK inhibitors, targeting STAT signaling
is emerging as an attractive approach to inhibit tumo-
rigenesis. Various strategies have been employed to in-
fluence STAT signaling at multiple levels, though theseapproaches are still at early stage and only supported by
pre-clinical data [13,100-107]. Further advancement in
understanding the molecular events and refining the tar-
gets can potentially lead to further clinical benefit. Si-
multaneous intervention at multiple levels of the signaling
cascade by combining different targeting agents may offer
additional advantages and is worthwhile studying.
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